Buchumschlag

Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer’s disease

Synaptic degeneration is a major hallmark of Alzheimer’s disease (AD) and the best pathological correlate of cognitive dysfunction. Synaptic markers are therefore a highly desired read-out for patient diagnosis and possible follow-up in clinical trials. Several synaptic markers for AD are described...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Oeckl, Patrick (VerfasserIn) , Halbgebauer, Steffen (VerfasserIn) , Straub, Sarah (VerfasserIn) , Arnim, Christine von (VerfasserIn) , Diehl-Schmid, Janine (VerfasserIn) , Frölich, Lutz (VerfasserIn) , Grimmer, Timo (VerfasserIn) , Hausner, Lucrezia (VerfasserIn) , Denk, Johannes (VerfasserIn) , Jahn, Holger (VerfasserIn) , Steinacker, Petra (VerfasserIn) , Weishaupt, Jochen H. (VerfasserIn) , Ludolph, Albert C. (VerfasserIn) , Otto, Markus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 26, 2020
In: Journal of proteome research
Year: 2020, Jahrgang: 19, Heft: 3, Pages: 1310-1318
ISSN:1535-3907
DOI:10.1021/acs.jproteome.9b00824
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1021/acs.jproteome.9b00824
Volltext
Verfasserangaben:Patrick Oeckl, Steffen Halbgebauer, Sarah Anderl-Straub, Christine A. F. von Arnim, Janine Diehl-Schmid, Lutz Froelich, Timo Grimmer, Lucrezia Hausner, Johannes Denk, Holger Jahn, Petra Steinacker, Jochen H. Weishaupt, Albert C. Ludolph, and Markus Otto
Beschreibung
Zusammenfassung:Synaptic degeneration is a major hallmark of Alzheimer’s disease (AD) and the best pathological correlate of cognitive dysfunction. Synaptic markers are therefore a highly desired read-out for patient diagnosis and possible follow-up in clinical trials. Several synaptic markers for AD are described in cerebrospinal fluid (CSF), but studies in blood have failed so far. Using quantitative mass spectrometry (IP-MS, MRM) we observed increased concentrations of the presynaptic protein beta-synuclein (βSyn) in CSF and blood of AD patients (n = 64, p < 0.01) and confirmed this finding in two validation cohorts (AD: n = 40 and n = 49, controls: n = 44 and n = 25). βSyn was already increased in patients with mild cognitive impairment (p < 0.01) and was also markedly increased in Creutzfeldt-Jakob disease (CJD; n = 25, p < 0.001) but not behavioral variant frontotemporal dementia (n = 16), dementia with Lewy bodies/Parkinson’s disease dementia (n = 13), Parkinson’s disease (n = 25), or amyotrophic lateral sclerosis (n = 30). The diagnostic sensitivity and specificity for CJD versus other neurodegenerative diseases was ≥96%. These findings suggest βSyn as a candidate blood marker for synaptic degeneration that might be used in clinical AD trials and patient follow-up as part of the recently suggested ATN biomarker panel. It can also serve in the differential diagnosis of CJD.
Beschreibung:Gesehen am 08.07.2021
Beschreibung:Online Resource
ISSN:1535-3907
DOI:10.1021/acs.jproteome.9b00824

Ähnliche Einträge